Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480568 · ClinicalTrials.gov registry record · Phase 3
Alirocumab in Patients on a Stable Dialysis Regimen
A Phase 3 study, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT03480568 is a Phase 3 study that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT03480568, a Phase 3 study, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.
Interventions
- DRUG Alirocumab 150 MG/ML [Praluent]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03480568
The ClinicalTrials.gov registry entry for NCT03480568 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alirocumab 150 MG/ML [Praluent] is the first listed.
NCT03480568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03480568 about?
NCT03480568 is a clinical study titled "Alirocumab in Patients on a Stable Dialysis Regimen". 12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. S...
What is the current status of trial NCT03480568?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2018-05-01. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03480568?
The interventions under investigation include: Alirocumab 150 MG/ML [Praluent] (DRUG).
Who is sponsoring clinical trial NCT03480568?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.